Pfizer Inc. (NYSE:PFE) Position Reduced by Mirova

Mirova decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 72,215 shares of the biopharmaceutical company’s stock after selling 8,488 shares during the period. Mirova’s holdings in Pfizer were worth $1,916,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new stake in Pfizer in the fourth quarter worth $31,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.4 %

NYSE PFE opened at $22.13 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $125.50 billion, a PE ratio of 15.69, a P/E/G ratio of 0.64 and a beta of 0.67. The stock has a 50-day simple moving average of $24.88 and a 200 day simple moving average of $26.17. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group lowered their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 8th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.07.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.